Sulforaphane (mainly Broccoli) / chemoP Cancer Research Results

SFN, Sulforaphane (mainly Broccoli): Click to Expand ⟱
Features:
Sulforaphane is an isothiocyanate derived from glucoraphanin, a compound found predominantly in cruciferous vegetables such as broccoli, Brussels sprouts, and cabbage. It is well known for its potent antioxidant and detoxification properties and has gained significant attention for its potential chemopreventive and anticancer effects.

Summary
1.primarily attenuates both DNMTs and HDACs, individually suppressing DNA hypermethylation and histones deacetylation, ultimately upregulating NRF2 (best known for NRF2↑)
2.Antioxidant Activity:
• Nrf2 activation leads to the upregulation of a host of antioxidant and detoxification enzymes (e.g., glutathione S-transferase, NAD(P)H:quinone oxidoreductase 1, heme oxygenase-1), which in turn decrease oxidative stress and lower ROS levels.
3.Pro-oxidant Effects in Cancer Cells and Under High-Dose Conditions (>=10uM?)
• In certain cancer cell types or at higher concentrations, sulforaphane can paradoxically lead to an increase in ROS levels.
• The elevated ROS may overwhelm the cancer cells’ antioxidant defenses, leading to oxidative stress–mediated cell death (apoptosis).
• This context-dependent pro-oxidant effect has been explored for its potential in selectively targeting cancer cells while leaving normal cells less affected.

- Might not be a good candidate for pro-oxidant strategy depending on concentration >10uM?.
- Strong Activation of Nrf2 (best known for) at low to moderate concentrations, hence reduces oxidative stress in both cancer and normal cells.
- AMPK signaling activated by SFN, high concentrations of ROS are produced
- ROS generation also results in depletion of GSH levels
- HIF-1α and VEGF inhibitor
- Might be effective against cancer stem cells
- But I would not combine that with radiation, as Sulforaphane activates the anti-oxidant master regulator of cells.
- “I very much agree: Sulforaphane is a very good addition, even more when the choice is an anti-oxidant therapy”
- well known as HDAC inhibitor (typically 5-10um concentrations)
-A transient decrease in HDAC activity has also been observed in healthy humans 3 h after providing a daily 200 µM SFN dose, resulting in a plasma concentration of SFN metabolites of 0.1–0.2 µM.


Dose/Bioavailabilty information:
SFN at a daily dose of 2.2 µM/kg body weight, with a mean plasma level of 0.13 µM Sprout 127.6 grams = 205uM±19.9 content yields SFN 0.5 to 2uM in plasma.
However, it is important to consider that at lower doses, specifically 2.5 μM, SFN resulted in a slight increase in cell proliferation by 5.18–11.84% within a 6 to 48 h treatment window.
-A therapeutic dose starts at approx 60 grams of the sprouts.
-100 g of Broccoli sprouts contain about 15–20 mg of sulforaphane
–Organic Broccoli Sprout Powder (Health Ranger) – Avmacol® – NanoPSA (a blend of NanoStilbene™ and Broccoli Sprout Extract).
- -750 mg Sulforaphane Glucosinolate in Daily One Serving (2 capsules) (30mg Sulforaphane)

Total sulforaphane metabolite concentration in plasma was the highest (>2 μM) at 3 h in human subjects who consumed fresh broccoli sprouts (40g)
-human studies with broccoli sprouts or extracts report plasma sulforaphane levels in the low micromolar range (typically 1–2 µM) after ingesting realistic, food-based quantities of sprouts (often in the range of 30–50 g of sprouts or a concentrated extract).

BroccoSprouts are young broccoli sprouts that have garnered attention because they contain high amounts of glucoraphanin—a precursor molecule to sulforaphane. Studies have shown that broccoli sprouts can have sulforaphane precursor levels (i.e., glucoraphanin levels) that are 10 to 100 times higher than those found in mature broccoli heads. Glucoraphanin content in broccoli sprouts can range anywhere from about 30 to over 100 mg per 100 grams of fresh sprouts. Once activated (e.g., during consumption when myrosinase acts on glucoraphanin), these levels translate into a significant sulforaphane yield, meaning that even a small amount of broccoli sprouts can deliver a potent dose of this bioactive compound.

Importantly, glucoraphanin itself is not bioactive. Rather, enzymatic hydrolysis by myrosinase, present in the plant tissue or in the mammalian microbiome, is necessary to form the active component, SFN.
- GFN (glucoraphanin) is hydrolyzed in vivo to SFN via the myrosinase, which is present in gut bacteria as well as the plant itself (also in Radish)
- Do not cook the vegetables, or if you do add myrosinase back in by adding radish.
- mild heat of broccoli (60–70 °C) inactivated ESP and preserved myrosinase and increased SF yield 3–7-fold
- chewing of fresh broccoli sprouts increases the interaction of glucosinolates with myrosinase and consequently, increases the bioavailability of SFN in the body

-Note half-life 2-3 hrs.
BioAv is good (15-80%) but requires myrosinase
Pathways:
- induce ROS production
- ROS↑ related: MMP↓(ΔΨm), ER Stress↑, UPR↑, GRP78↑, Ca+2↑, Cyt‑c↑, Caspases↑, DNA damage↑, cl-PARP↑, HSP↓, Prx,
- Lowers AntiOxidant defense in Cancer Cells: NRF2↓(contrary, actually most raises NRF2), TrxR↓**, GSH↓, Catalase↓(contrary), HO1↓(contrary), GPx↓
- Raises AntiOxidant defense in Normal Cells: ROS↓, NRF2↑, SOD↑, GSH↑, Catalase↑,
- lowers Inflammation : NF-kB↓, COX2↓, p38↓, Pro-Inflammatory Cytokines : NLRP3↓, IL-1β↓, TNF-α↓, IL-6↓, IL-8↓
- inhibit Growth/Metastases : TumMeta↓, TumCG↓, EMT↓, MMPs↓, MMP2↓, MMP9↓, IGF-1↓, VEGF↓, ROCK1↓, FAK↓, RhoA↓, NF-κB↓, CXCR4↓, α-SMA↓, ERK↓
- reactivate genes thereby inhibiting cancer cell growth : HDAC↓, DNMTs↓, EZH2↓, P53↑, HSP↓, Sp proteins↓,
- cause Cell cycle arrest : TumCCA↑, cyclin D1↓, cyclin E↓, CDK2↓, CDK4↓, CDK6↓,
- inhibits Migration/Invasion : TumCMig↓, TumCI↓, TNF-α↓, FAK↓, ERK↓, EMT↓,
- inhibits glycolysis /Warburg Effect and ATP depletion : HIF-1α↓, PKM2↓, cMyc↓, GLUT1↓, LDH↓, LDHA↓, HK2↓, ECAR↓, OXPHOS↓, GRP78↑, GlucoseCon↓
- inhibits angiogenesis↓ : VEGF↓, HIF-1α↓, Notch↓, PDGF↓, EGFR↓, Integrins↓,
- inhibits Cancer Stem Cells : CSC↓, Hh↓, GLi↓, GLi1↓, CD133↓, β-catenin↓, sox2↓, notch2↓, nestin↓, OCT4↓,
- Others: PI3K↓, AKT↓, JAK↓, STAT↓, Wnt↓, β-catenin↓, AMPK, ERK↓, 5↓, - SREBP (related to cholesterol).
- Synergies: chemo-sensitization, chemoProtective, RadioSensitizer, RadioProtective, Others(review target notes), Neuroprotective, Cognitive, Renoprotection, Hepatoprotective, CardioProtective,

- Selectivity: Cancer Cells vs Normal Cells

Rank Pathway / Axis Cancer Cells Normal Cells Label Primary Interpretation Notes
1 NRF2 / KEAP1 antioxidant response ↑ NRF2 (often insufficient for rescue) ↑ NRF2 (protective) Driver Electrophile-driven stress response Sulforaphane covalently modifies KEAP1, activating NRF2 signaling
2 Histone deacetylases (HDACs) ↓ HDAC activity ↔ mild modulation Driver Epigenetic reprogramming HDAC inhibition alters transcription of cell-cycle and apoptosis genes
3 Reactive oxygen species (ROS) ↑ ROS (transient / stress-inducing) ↓ ROS Secondary Redox signaling perturbation ROS rise reflects electrophilic stress rather than classic redox cycling
4 Cell cycle regulation ↑ G2/M or G1 arrest ↔ largely spared Secondary Cytostatic growth control Cell-cycle arrest is a prominent phenotype in cancer cells
5 Intrinsic apoptosis ↑ apoptosis (context-dependent) ↔ protected Phenotypic Threshold-dependent cell death Apoptosis occurs when stress exceeds adaptive capacity
6 NF-κB signaling ↓ NF-κB activation ↓ inflammatory NF-κB tone Secondary Suppression of inflammatory survival programs NF-κB inhibition supports anti-proliferative and anti-inflammatory effects


chemoP, ChemoProtective: Click to Expand ⟱
Source:
Type:
Protects normal cells against the effect of Chemo.


Scientific Papers found: Click to Expand⟱
9173- ITCs,  SFN,    Dietary isothiocyanates and anticancer agents: exploring synergism for improved cancer management
- Review, Var, NA
Synergy↑, Our analysis reveals the potential of these synergies to augment therapeutic efficacy, mitigate chemoresistance, and minimize toxic effects, thereby opening avenues for therapeutic innovation.
AntiCan↑, Isothiocyanates, such as sulforaphane (SFN), allyl isothiocyanate (AITC), benzyl isothiocyanate (BITC), and phenethyl isothiocyanate (PEITC), are metabolized from glucosinolates and renowned for their potent anticancer properties.
chemoP↑, Beyond prevention, ITCs show promise in synergizing with conventional anticancer agents, potentially amplifying therapeutic efficacy while minimizing the adverse side effects typically associated with chemotherapy.
ChemoSen?, ITCs, notably SFN, have been shown to induce chemosensitization in cancer cells.
toxicity↓, At low doses, ITCs can promote the growth of both normal and cancer cells, whereas high doses are toxic to cancer cells.
ROS↑, At low concentrations, ITCs may activate mild oxidative stress, leading to the adaptive activation of protective pathways like Nrf2, enhancing cellular defenses against carcinogens. However, at therapeutic concentrations, ITCs exert pronounced cytoto
NRF2↑,
NF-kB↓, inhibition of the nuclear factor kappa B (NF-κB),
CYP1A1↓, Specifically, ITCs inhibit phase I enzymes, such as Cytochrome P450 enzymes (CYP1A1, CYP1A2, and CYP1B1), responsible for pro-carcinogens bioactivation.
CYP1A2↓,
CYP1B1↓,
TumCCA↑, By inducing cell cycle arrest, ITCs prevent cancer cells from entering mitosis, thereby impeding tumor growth and progression
PI3K↓, SFN has been identified to downregulate the PI3K/AKT/mTOR signaling pathway and upregulate the expression of PTEN, a tumor suppressor gene.
Akt↓,
mTOR↓,
PTEN↑,
BAX↑, SFN enhances the production of Bax, a pro-apoptotic protein, thereby promoting apoptosis in cancer cells.
ChemoSen↑, SFN can enhance the efficacy of chemotherapeutic agents such as cisplatin and doxorubicin (DOX)
Synergy↑, Furthermore, a tri-combination involving SFN, GEN, and sodium butyrate (NaB) resulted in even more pronounced synergistic inhibition in breast cancer, reaching a minimum CI value of 0.06 in MCF-7 cells
Synergy↑, The first study by Langner et al. (74) investigated a blend (referred to as MIX) of lycopene, SFN, quercetin, and curcumin. It revealed an additive effect in the reduction of colon cancer cell proliferation.
Synergy↑, The second study investigated the synergistic effects of SFN with curcumin and dihydrocaffeic acid (DA) against colon cancer cells
Synergy↑, Combining BITC and SFN proved more effective than either compound alone in reducing cell viability. This combination exhibited an enhanced reduction in pSTAT3 levels and an amplified increase in apoptosis, evident through PARP cleavage.
Synergy↑, Furthermore, the combination of SFN with AITC has demonstrated synergistic effects in non-small cell lung carcinoma cells, manifested by increased production of intracellular ROS and concomitant suppression of cancer cell proliferation
Dose↝, In this review, we define low doses of SFN as 1–5 μM and high doses as above 10 μM, based on concentrations used in cited studies.
Synergy↑, Additionally, up to 1.5 μM SFN can enhance cisplatin sensitivity through the accumulation of intracellular cisplatin in ovarian cancer cells

2553- SFN,    Mechanistic review of sulforaphane as a chemoprotective agent in bladder cancer
- Review, Bladder, NA
antiOx↓, SFN is a bioactive compound with both antioxidant and anti-inflammatory properties.
Inflam↓,
ChemoSen↑, SFN also improves the efficacy of certain traditional chemotherapeutic regimens
ROS⇅, A lesser established mechanism proposed by Li, et al. is that SFN induces mild increases ROS, leading to transcription factor EB (TFEB) activation. TFEB plays a role in activating antioxidant response elements and...ultimately reducing overall oxidat
*NRF2↑, SFN treatment increased Nrf2 and, therefore, glutathione levels
*GSH↑,
Catalase↑, Cancer cells treated with SFN showed higher catalase levels, heme oxygenase 1, and NAD(P)
HO-1↑,
NAD↑,
chemoP↑, Taken together, these studies provide strong evidence for the chemoprotective nature of SFN in various human epithelial cancers, including those of the bladder.


Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↓, 1,   Catalase↑, 1,   HO-1↑, 1,   NRF2↑, 1,   ROS↑, 1,   ROS⇅, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

NAD↑, 1,  

Cell Death(tgid=5) ⓘ

BAX↑, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

Akt↓, 1,   mTOR↓, 1,   PI3K↓, 1,   PTEN↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

TumCCA↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

Inflam↓, 1,   NF-kB↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

ChemoSen?, 1,   ChemoSen↑, 2,   CYP1A1↓, 1,   CYP1A2↓, 1,   CYP1B1↓, 1,   Dose↝, 1,   Synergy↑, 7,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 1,   chemoP↑, 2,   toxicity↓, 1,  
Total Targets: 25

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

GSH↑, 1,   NRF2↑, 1,  
Total Targets: 2

Scientific Paper Hit Count for: chemoP, ChemoProtective
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:156  Target#:1171  State#:%  Dir#:%
wNotes=on sortOrder:rid,rpid

 

Home Page